Developing vaccines to improve treatment for Type 1 Diabetes
Machine learning optimized autoimmune therapeutics with a focus on Type 1 Diabetes
This study is working on new vaccines to help treat Type 1 Diabetes by finding specific proteins that the immune system mistakenly attacks, and it aims to create a vaccine that can help calm down that immune response, making it better for people with the condition.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Think Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Newton, United States) |
| Project ID | NIH-10929966 on NIH RePORTER |
What this research studies
This research focuses on creating new vaccines aimed at treating autoimmune diseases, specifically Type 1 Diabetes (T1D). The team will develop a novel assay called the Multiplexed Multi-antigen Activation Assay (MMAA) to identify self-antigens recognized by T cells in T1D patients. Using these self-antigens, they will design multi-epitope tolerization vaccines and test their effectiveness in expanding regulatory T cells from blood samples of T1D donors. Advanced machine learning techniques will be employed to enhance the vaccine's effectiveness across diverse populations.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Type 1 Diabetes who may benefit from new therapeutic approaches.
Not a fit: Patients with other types of diabetes or autoimmune diseases unrelated to Type 1 Diabetes may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that improve treatment outcomes for patients with Type 1 Diabetes.
How similar studies have performed: Other research has shown promise in using machine learning and immunogenicity assays for developing autoimmune therapies, indicating a potential for success in this novel approach.
Where this research is happening
Newton, United States
- Think Therapeutics, INC. — Newton, United States (Active)
Researchers
- Principal investigator: Gifford, David K — Think Therapeutics, INC.
- Study coordinator: Gifford, David K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.